Results-6 patients (10%) in the amiodarone group and 14 (23%) in the placebo group needed treatment for arrhythmias (95% confidence interval (95% CI) for the difference between groups was 0 to 26%, p = 0.05). The incidence of supraventricular tachycardia detected clinically and requiring treatment was lower in the amiodarone group (8% amiodarone v 20% placebo, 95% CI 0 to 24%, p = 0.07).
The incidence detected by 24 hour Holter monitoring was similar (17% amiodarone v 20% placebo). Untreated arrhythmias in the amiodarone group were either clinically benign and undetected (n = 3) or the ventricular response rate was slow (n = 2). Age > 60 years was a positive risk factor for the development of supraventricular tachycardia in the amiodarone group but not in the placebo group duration) occurred in five (8%) amiodarone and seven (12%) placebo patients.
There was an increased incidence of supraventricular tachycardia with age >60 years in the amiodarone but not in the placebo group. Anginal class, ejection fraction at entry, right coronary endarterectomy, and ischaemic time had no significant effect on the incidence of supraventricular tachycardia (table 3) .
Three amiodarone treated patients had adverse events. One cerebrovascular accident, and one acute sinus node dysfunction (withdrawn from study) were not considered to be drug related; bradycardia in one patient required ending the treatment. Two patients in the amiodarone group did not complete the study, refusing to continue because of nightmares. One adverse event (rash) occurred in the placebo group.
Time to discharge from hospital was similar in the two groups (median seven (six to 15) days amiodarone, seven (six to 38) days placebo).
Discussion
Amiodarone significantly reduced the incidence of clinically significant tachycardia in this study. In the supraventricular subgroup, Holter monitoring data showed that the effect of amiodarone was due to reduction of the ventricular response rate rather than overall prevention of the arrhythmias. The reduction in the ventricular response rate in the presence of supraventricular tachycardia may be explained by prolongation of the refractory period of the atrioventricular node.25 Amiodarone also has calcium slow channel blocking effects.26 Lengthening of atrioventricular nodal refractoriness and noncompetitive adrenergic antagonism seem to be the main antiarrhythmic effects of intravenous amiodarone.24 The ability of amiodarone to lower the ventricular response rate in the presence of supraventricular tachycardia has been previously shown. 27 The detection of all supraventricular tachycardias in the first five postoperative days is consistent with other reports. Although not conclusively shown, the delayed occurrence of these arrhythmias in the amiodarone group may reflect their suppression particularly by the intravenous infusion given over the first 24 hours.
The incidence of potentially serious ventricular arrhythmias detected by Holter monitoring was reduced by amiodarone. Prolongation of the duration of the action potential is a potent antifibrillatory mechanism and amiodarone is known to be highly effective in preventing recurrent ventricular tachycardia or ventricular fibrillation resistant to other antiarrhythmic drugs. Ventricular arrhythmias that required intervention occurred rarely in our study, and it was therefore not possible to show any advantage of amiodarone for the prevention of these, but salvos of ventricular tachycardia recorded by Holter monitoring were considerably reduced.
A significant decline in heart rate occurred during infusion of amiodarone, suggesting non-competitive sympathetic blockade or slowing of phase 4 depolarisation within the sinus node.12 13 This effect of slowing of sinus rhythm particularly in patients already on fi blockers may preclude routine use of amiodarone in patients undergoing coronary artery surgery and there was some increased need for chronotropic support in the first 24 hours. In this series, however, heart rate was sufficiently slow to have to end the treatment in only one patient.
The development of acute sinus node dysfunction in another patient was not considered to be drug related by an independent cardiologist as it occurred shortly after surgery, did not improve after the end of the infusion, and required insertion of a permanent pacemaker. Two patients did not wish to continue the study after nightmares, a known side effect of amiodarone and therefore possibly drug related.
The difference in frequency of arrhythmias between age groups suggests that amiodarone may be less effective as prophylaxis in those over 60 years. There is also some evidence that the use of f-blockers for the prevention of atrial fibrillation or flutter is less effective with increasing age.28 Several studies have now established that increasing age is the most important known risk factor for the development of supraventricular tachycardia after coronary artery surgery.28 29 That this was not found in our placebo group may be explained by the relatively small size of the population.
In conclusion, amiodarone reduced the incidence of clinically important arrhythmias. In the supraventricular subgroup, its effect appeared to be mainly due to a decrease in the ventricular response rate rather than overall prevention of arrhythmias. An increased incidence of bradycardia is a potential disadvantage that deters us from advocating the routine use of amiodarone for the prophylaxis of tachycardia after coronary artery surgery. 
